Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.
Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidol. 2013 May-Jun; 7(3 Suppl):S11-5.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Humans
Hyperlipoproteinemia Type II
Lipoproteins, LDL
Proprotein Convertase 9
Proprotein Convertases
Serine Endopeptidases
authors with profiles
Michael H. Davidson